GleamWall
中文EN

PRPH ProPhase Labs, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 868278 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY138.9%
TTM net income YoY45.8%
TTM EPS YoY91.5%
Revenue 3-yr CAGR-63.4%
Net income 3-yr CAGR—

Margins

Gross margin16.8%
Operating margin-404.5%
Net margin-583.9%
FCF margin—
EBITDA margin-320.1%

Returns

ROE-539.7%
ROA-45.2%
ROIC (approx.)-302.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets105.4%
Debt / equity—
Current ratio0.05x
Interest coverage-2.15x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$1.01M$1.17M$784,000$883,000$1.25M$1.43M-$2.48M$1.42M
Cost of revenue$785,000$874,000$537,000$1.01M$513,000$905,000-$3.41M$1.20M
Gross profit$226,000$295,000$247,000-$123,000$734,000$526,000$924,000$215,000
R&D expense——$0$6,000$4,000$97,000$61,000$122,000
SG&A expense$2.87M$2.72M$5.97M$4.63M$4.62M$4.09M$15.43M$6.57M
Operating income-$2.65M-$2.43M-$5.73M-$4.76M-$3.89M-$3.66M-$14.57M-$6.48M
Interest expense$791,000$651,000$4.26M$1.55M$587,000$539,000$1.03M$993,000
Pretax income-$3.04M-$3.80M-$8.02M-$7.00M-$3.69M-$4.68M-$15.96M-$7.47M
Income tax$12,000$1.37M-$622,000-$157,000$779,000$0$14.56M-$2.51M
Net income-$3.05M-$5.17M-$7.40M-$6.84M-$4.47M$3.97M-$34.36M-$6.59M
EBITDA-$2.02M-$1.46M-$4.76M-$4.07M-$2.88M-$2.18M-$13.04M-$4.95M
EPS (basic)-0.22-0.42—-0.16-1.081.13—-0.35
EPS (diluted)-0.22-0.42—-0.16-1.081.13—-0.35
Weighted avg. shares (diluted)14.02M12.32M—41.54M4.15M3.52M—19.08M
Banking
Provision for credit losses——————$0$0
Balance sheet
Cash & equivalents$20,000$31,000$90,000$405,000$169,000$88,000$678,000$501,000
Short-term investments——$0—$2,000—$3.13M$2,000
Receivables$1.54M$1.54M$1.54M$3.28M$20.09M$20.20M$20.06M$31.64M
Inventory$70,000$70,000$70,000$266,000$830,000$1.15M$1.14M$3.97M
Current assets$2.80M$2.85M$3.15M$7.77M$24.57M$24.77M$30.64M$42.23M
PP&E, net$1.39M$1.71M$2.03M$2.35M$3.58M$6.57M$7.50M$13.85M
Goodwill$3.97M$3.97M$3.97M$3.97M$5.23M$5.23M$5.23M$5.23M
Intangibles$5.88M$6.52M$7.17M$7.81M$8.46M$9.10M$9.75M$10.40M
Total assets$57.41M$58.47M$59.87M$65.70M$42.04M$50.11M$63.20M$91.81M
Current liabilities$58.09M$55.67M$53.08M$55.29M$25.63M$24.05M$32.13M$28.70M
Short-term debt—————$2.45M$3.21M$2.67M
Total liabilities$60.52M$58.90M$56.36M$58.84M$30.61M$34.99M$55.85M$53.68M
Shareholders' equity-$3.11M-$435,000$3.51M$6.86M$11.44M$15.12M$7.35M$38.13M
Shares outstanding14.02M14.02M8.97M41.54M41.54M41.54M2.99M19.08M
Cash flow statement
Operating cash flow-$78,000-$748,000-$1.23M-$3.49M-$247,000-$3.38M-$3.52M-$4.04M
Capital expenditure——$0$0$0$0-$235,000-$1,000
Free cash flow——-$1.23M-$3.49M-$247,000-$3.38M-$3.28M-$4.04M
Investing cash flow$0$12,000$0$0$67,000$853,000-$40,000-$97,000
Financing cash flow$67,000$677,000$915,000$3.72M$261,000$1.94M$3.73M$2.86M
Depreciation & amortization$623,000$962,000$963,000$698,000$1.01M$1.48M$1.52M$1.53M
Stock-based compensation$375,000$390,000$433,000$400,000$500,000$521,000$617,000$600,000
Share buybacks——————$0$0

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.